文献速递浆细胞疾病造血干细胞移植与细胞治疗

VTD方案联合双次自体造血干细胞移植治疗新诊断多发性骨髓瘤的长期随访分析

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
PubMed 文献 · Lancet Haematol · 2020-01-01

GIMEMA-MMY-3006研究比较VTD与TD方案诱导及巩固后行双次自体造血干细胞移植的疗效。VTD是改善生存的独立预测因素。

要点

  • VTD组10年无进展生存率34%,显著优于TD组的17%。
  • VTD组10年总生存率60%,显著优于TD组的46%。
  • VTD方案联合双次自体移植应作为适合高强度化疗患者的一线金标准。

核心结论

  • VTD方案联合双次自体造血干细胞移植可显著改善新诊断多发性骨髓瘤患者的长期无进展生存和总生存。

研究设计与样本

  • 随机、开放标签、3期研究,纳入意大利73个中心480例18-65岁初治症状性多发性骨髓瘤患者,按1:1随机接受VTD或TD方案诱导及巩固,后行双次自体造血干细胞移植。

关键数值与推荐

  • TD方案:沙利度胺同VTD;地塞米松每周期总320 mg(第1-4、9-12天各40 mg)。
  • 诱导3个21天周期,双次自体移植后巩固2个35天周期。

临床怎么用

  • 对于适合高强度化疗的新诊断多发性骨髓瘤患者,含硼替佐米和免疫调节剂的VTD方案联合双次自体造血干细胞移植是金标准治疗。

局限性

  • 研究人群为18-65岁且Karnofsky体能状态评分≥60%的患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report the results from the final analysis of the study. METHODS: In this randomised, open-label, phase 3 study, patients aged 18-65 years with previously untreated symptomatic multiple myeloma and a Karnofsky Performance Status of 60% or higher were enrolled at 73 centres in Italy. Patients were randomised (1:1) by a web-based system to receive three 21-day cycles of thalidomide (100 mg daily orally for the first 14 days and 200 mg daily thereafter) plus dexamethasone (total 320 mg per cycle; 40 mg on days 1-2, 4-5, 8-9, and 11-12 in the VTD regimen, and 40 mg on days 1-4 and 9-12 in the TD regimen), either alone (TD group) or with bortezomib (1·3 mg/m2 intravenously on days 1, 4, 8, and 11; VTD group). After double autologous HSCT, patients received two 35-day cycles of either the VTD or TD regimen, according to random assignment, as consolidation therapy. The primary outcome was the rate of complete response and near complete response after induction (already reported). In this updated analysis we assessed long-term progression-free survival and overall survival (secondary endpoints of the study) with an extended 10-year median follow-up, and analysed the variables influencing survival. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, NCT01134484. FINDINGS: Between May 10, 2006, and April 30, 2008, 480 patients were enrolled and randomly assigned to receive VTD (241 patients) or TD (239 patients). Six patients withdrew consent before start of treatment. 236 (99 [42%] women) in the VTD group and 238 (102 [43%] women) in the TD group were included in the intention-to-treat analysis. The data cutoff date for this analysis was May 31, 2018. Median follow-up for surviving patients was 124·1 months (IQR 117·2-131·7). The 10-year progression-free survival estimate for patients in the VTD group was 34% (95% CI 28-41) compared with 17% (13-23) for the TD group (hazard ratio [HR] 0·62 [95% CI 0·50-0·77]; p<0·0001). 60% (95% CI 54-67) of patients in the VTD group were alive at 10 years versus 46% (40-54) of patients in the TD group (HR 0·68 [95% CI 0·51-0·90]; p=0·0068). VTD was an independent predictor of improved progression-free survival (HR 0·60 [95% CI 0·48-0·76]; p<0·0001) and overall survival (HR 0·68 [0·50-0·91]; p=0·010). The incidence of second primary malignancies per 100 person-years was 0·87 (95% CI 0·49-1·44) in the VTD group compared with 1·41 (0·88-2·13) in the TD group. INTERPRETATION: Incorporation of VTD into double autologous HSCT resulted in clinically meaningful improvements in long-term progression-free survival and overall survival, confirming that a regimen including bortezomib and an immunomodulatory drug is the gold standard treatment for patients with newly diagnosed myeloma who are fit for high-dose chemotherapy. FUNDING: Seràgnoli Institute of Haematology, University of Bologna, and BolognAIL.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Tacchetti P, Pantani L, Patriarca F, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020. PMID: 33242443. doi:10.1016/S2352-3026(20)30323-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。